Comparison of the Effects of Monounsaturated Fatty Acids and Polyunsaturated Fatty Acids on Liver Lipid Disorders in Obese Mice.
Mice
Animals
Humans
Fatty Acids, Monounsaturated
/ pharmacology
Mice, Obese
Non-alcoholic Fatty Liver Disease
/ etiology
Diabetes Mellitus, Type 2
/ metabolism
Mice, Inbred C57BL
Liver
/ metabolism
Fatty Acids, Unsaturated
/ metabolism
Fatty Acids
/ metabolism
Triglycerides
/ metabolism
Diet, High-Fat
/ adverse effects
Obesity
/ metabolism
hepatic steatosis
insulin resistance
obesity
targeted lipidomics
unsaturated fatty acids
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
19 Jul 2023
19 Jul 2023
Historique:
received:
12
06
2023
revised:
14
07
2023
accepted:
17
07
2023
medline:
31
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Obesity is a recognized epidemic worldwide, and the accumulation of excess free saturated fatty acids (SFAs) in cells induces cellular lipotoxic damage and increases the risk of a wide spectrum of metabolic diseases including type 2 diabetes (T2D) and nonalcoholic fatty liver disease (NAFLD). Monounsaturated fatty acids (MUFAs) and polyunsaturated fatty acids (PUFAs) have been reported to combat SFA-induced cellular damage. However, the comparative studies of the two types of unsaturated fatty acids (UFAs) are still limited. We investigated the effects of different MUFAs and PUFAs in the human hepatocyte line L-02 cells in vitro, and in high-fat-diet (HFD)-induced obese C57BL/6 mice in vivo. The results of the in vitro study showed that SFAs induced significant cellular lipotoxic damage, but the combination of MUFAs/PUFAs with SFAs significantly improved the impaired cell viability. Particularly, oleic acid (OA) was superior to eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA), and arachidonic acid (AA) in terms of its anti-apoptotic effect and inhibition of endoplasmic reticulum (ER) stress. In vivo, both olive-oil-enriched (HFD + OO) and fish-oil-enriched high-fat diets (HFD + FO) reduced hepatic steatosis and improved insulin sensitivity in obese mice. However, FO induced an abnormal increase in serum aspartate aminotransferase (AST) and an increase in the oxidative stress indicator Malondialdehyde (MDA). Liver-targeted lipidomic analysis showed that liver lipid metabolites under the two types of UFA dietary interventions differed from the HFD group, modulating the abundance of some lipid metabolites such as triglycerides (TGs) and glycerophospholipids. Furthermore, the FO diet significantly increased the abundance of the associated FA 20:5 long-chain lipid metabolites, whereas the OO diet regulated the unsaturation of all fatty acids in general and increased the abundance of FA 18:1 in the overall lipid metabolites, especially TGs, which may primarily contribute to the FO, and OO drove protection in NAFLD.
Identifiants
pubmed: 37513618
pii: nu15143200
doi: 10.3390/nu15143200
pmc: PMC10386220
pii:
doi:
Substances chimiques
Fatty Acids, Monounsaturated
0
Fatty Acids, Unsaturated
0
Fatty Acids
0
Triglycerides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Natural Science Foundation of China
ID : 82170590
Organisme : National Natural Science Foundation of China
ID : 81870609
Organisme : National Natural Science Foundation of China
ID : 82170075
Organisme : Science and Technology Department of Sichuan Province project funding
ID : 2021YFH0061
Organisme : the 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University
ID : ZYGD18014
Références
Anal Bioanal Chem. 2011 Jul;400(9):2933-41
pubmed: 21617979
Mol Nutr Food Res. 2015 Sep;59(9):1791-802
pubmed: 26080997
Nature. 2011 May 26;473(7348):528-31
pubmed: 21532591
Clin Nutr. 2018 Oct;37(5):1474-1484
pubmed: 29249532
J Lipid Res. 2006 Sep;47(9):1928-39
pubmed: 16751624
Life Sci. 2018 Jun 15;203:291-304
pubmed: 29709653
Prostaglandins Leukot Essent Fatty Acids. 2015 Mar;94:49-54
pubmed: 25481335
J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Sep 1;1093-1094:147-157
pubmed: 30029201
Metabolomics. 2019 Aug 17;15(8):114
pubmed: 31422486
Exp Cell Res. 2015 Dec 10;339(2):397-406
pubmed: 26433148
Biochem Biophys Res Commun. 2006 Aug 4;346(3):739-45
pubmed: 16781673
Expert Rev Gastroenterol Hepatol. 2019 Aug;13(8):739-749
pubmed: 31215262
Nutr Metab Cardiovasc Dis. 2020 Apr 12;30(4):709-716
pubmed: 32007335
J Nutr Biochem. 2015 Sep;26(9):949-59
pubmed: 26007287
PLoS One. 2014 Apr 23;9(4):e96221
pubmed: 24760204
Lipids. 2014 May;49(5):431-44
pubmed: 24627299
Biochem Biophys Res Commun. 2022 Jun 11;608:90-95
pubmed: 35397428
Am J Physiol Endocrinol Metab. 2020 Dec 1;319(6):E961-E980
pubmed: 33044844
PLoS Med. 2016 Jul 19;13(7):e1002087
pubmed: 27434027
Mol Nutr Food Res. 2021 May;65(9):e2001192
pubmed: 33561904
J Nutr Biochem. 2018 Aug;58:1-16
pubmed: 29621669
Biochim Biophys Acta. 2008 Feb;1778(2):466-71
pubmed: 18068112
Endocrine. 2019 Jun;64(3):512-524
pubmed: 30778898
J Cell Biol. 2004 Oct 11;167(1):35-41
pubmed: 15466483
Diabetologia. 2019 Sep;62(9):1539-1549
pubmed: 31346658
Curr Opin Immunol. 2016 Dec;43:60-66
pubmed: 27718448
Nutr Metab (Lond). 2020 Jan 30;17:11
pubmed: 32021639
Biomolecules. 2020 Jul 31;10(8):
pubmed: 32751983
Nutrients. 2020 Sep 11;12(9):
pubmed: 32932796
J Biol Chem. 2004 Aug 27;279(35):37030-9
pubmed: 15215242
Nutrition. 2023 Feb;106:111910
pubmed: 36459845
Int J Cancer. 1997 Sep 17;72(6):1078-87
pubmed: 9378543
Exp Cell Res. 2023 Aug 15;429(2):113655
pubmed: 37253404
Apoptosis. 2009 Dec;14(12):1484-95
pubmed: 19421860
Visc Med. 2016 Oct;32(5):329-334
pubmed: 27921044
Life Sci. 2008 Mar 26;82(13-14):684-91
pubmed: 18272185